Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

Mental Health and Physical Activity, published by Elsevier Science LTD, is an esteemed journal in the realm of Applied Psychology and Psychiatry and Mental Health, thriving since 2008 and continuing its valuable contribution through 2024. With an impressive impact factor showcased by its ranking in the Q2 category for Applied Psychology and Q1 for Psychiatry and Mental Health, the journal supports the dissemination of innovative research that explores the intricate connections between mental well-being and physical activity. Positioned in the Netherlands, the journal offers a robust platform for researchers, clinicians, and students to share insights and develop new interventions that foster better mental health outcomes through physical engagement. While the journal currently does not provide open access options, its commitment to high-quality peer-reviewed content makes it a critical resource for those dedicated to advancing knowledge in the fields of psychology and mental health. With rankings placing it in the top fraction of its peer group, Mental Health and Physical Activity remains an essential cerebral space for impactful dialogue and research in the study of mental health promotion.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

DEPRESSION AND ANXIETY is a leading academic journal published by WILEY, dedicated to presenting cutting-edge research in the fields of clinical psychology, psychiatry, and mental health. With an impressive impact factor underscoring its prominence—ranked in the top quartile (Q1) for both clinical psychology and psychiatry, and occupying the 7th and 20th ranks in Scopus respectively—this journal serves as a pivotal resource for researchers, professionals, and students alike. Since its inception in 1996 and continuing through 2024, DEPRESSION AND ANXIETY has been at the forefront of disseminating findings that significantly impact our understanding of mental health issues. The journal's rigorous peer-review process ensures the highest quality of published works, making it an essential platform for scholars aiming to advance knowledge and contribute meaningfully to the mental health discourse.

ACTAS ESPANOLAS DE PSIQUIATRIA, published by the renowned JUAN JOSE LOPEZ-IBOR FOUNDATION, serves as a vital resource in the field of psychiatry and mental health, particularly within the Spanish-speaking academic community. With its ISSN 1139-9287 and E-ISSN 1578-2735, this journal has been a critical platform for disseminating high-quality research since its inception in 1996 and continues to contribute valuable insights until 2024. As a recognized journal in the Q3 category of psychiatry and mental health, it ranks 387 out of 567 in Scopus, placing it within the 31st percentile, thereby indicating a growing influence among its peers. The journal’s open access options enhance its accessibility, encouraging a broader readership to engage with contemporary research issues in mental health. Researchers, professionals, and students alike will find ACTAS ESPANOLAS DE PSIQUIATRIA essential for staying informed on the latest developments and innovations in psychiatric practice and research.

Schizophrenia Research is a premier academic journal focused on innovative research within the domain of psychiatry and mental health, published by Elsevier. With its ISSN 0920-9964 and E-ISSN 1573-2509, the journal has established a strong presence since its inception in 1988, evolving to publish cutting-edge findings up to 2024. Positioned in Q1 in Psychiatry and Mental Health and Q2 in Biological Psychiatry, it ranks impressively in the 83rd percentile among its peers, according to Scopus, ranking #93/567 in the field of Medicine, and #12/51 in Neuroscience. This journal serves as a vital platform for the dissemination of significant scientific advancements and theoretical insights into schizophrenia, fostering a deeper understanding of mental illnesses. Although it operates on a subscription basis, its critical role in informing both ongoing research and clinical practices cannot be overstated, making it an essential resource for researchers, clinicians, and students alike. Join a global community dedicated to improving mental health outcomes and advancing the study of schizophrenia through this reputable publication.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

British Journal of Psychiatry, published by Cambridge University Press, stands as a pivotal resource in the realm of mental health and psychiatry. With an impressive impact reflected in its Q1 classifications in both Medicine (miscellaneous) and Psychiatry and Mental Health, this esteemed journal ranks 23rd out of 567 in its field according to Scopus, achieving an exceptional 96th percentile. Since its inception in 1963, the journal has continued to push the boundaries of research and discourse, serving as a platform for groundbreaking studies that enhance our understanding of psychiatric conditions and promote effective therapeutic strategies. Though it does not operate with an open-access model, the British Journal of Psychiatry remains an essential publication for researchers, clinicians, and students alike, offering in-depth insights and innovative findings that are crucial for navigating the complexities of mental health.